Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells
Rachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, Ming-yuan Gao, David H Segal, Zhen Xu, Andreas Strasser, David CS Huang
CELL DEATH AND DIFFERENTIATION | NATURE PUBLISHING GROUP | Published : 2020
Awarded by Australian National Health and Medical Research Council
Awarded by Leukemia & Lymphoma Society of America
Awarded by Cancer Australia and Cure Cancer PdCCRS grant
This work was supported by grants and fellowships from the Australian National Health and Medical Research Council (programme grant no. 1016701, Senior Principal Research Fellowship 1020363 to AS and Principal Research Fellowship 1156024 to DCSH), the Leukemia & Lymphoma Society of America (Fellowship 5467-18 to RT and Specialized Center of Research grants no. 7001-13 and 7015-18 to AS and DCSH), a Spanish Ministry of Education Postdoctoral Fellowship to SA-D, a Cancer Australia and Cure Cancer PdCCRS grant 1186003 to RT, an Australian Government Research Training Program Scholarship to CG, as well as by operational infrastructure grants through the Australian Government Independent Research Institute Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support Program.